Evelo Biosciences to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020
July 23, 2020 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences to Present Clinical Data from Phase 1/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting
July 01, 2020 07:08 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences Announces Pricing of Public Offering of Common Stock
June 24, 2020 19:56 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered,...
Evelo Biosciences Announces Proposed Public Offering of Common Stock
June 24, 2020 16:01 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered,...
Evelo Biosciences Announces EDP1815 to Advance into Phase 2/3 TACTIC-E COVID-19 Trial
June 22, 2020 02:00 ET
|
Evelo Biosciences, Inc.
—Phase 2/3 platform trial sponsored by Cambridge University Hospitals NHS Foundation Trust——Experimental therapies with potential to prevent and treat complications of COVID-19——EDP1815 selected as...
Evelo Biosciences to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
June 16, 2020 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences to Present at Jefferies Virtual Healthcare Conference
May 28, 2020 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences Reports First Quarter Financial Results and Business Highlights
May 11, 2020 07:00 ET
|
Evelo Biosciences, Inc.
–Submitted investigational new drug (IND) application for a Phase 2 trial of EDP1815 for COVID-19; data readout expected during 2H 2020––Selected enteric capsule formulation of EDP1815 for Phase 2...
Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients
May 07, 2020 07:00 ET
|
Evelo Biosciences, Inc.
—Early intervention in hospitalized patients could help prevent progression of disease— —EDP1815 has demonstrated favorable tolerability and anti-inflammatory activity in a prior clinical trial——Data...
Evelo Biosciences to Report First Quarter 2020 Financial Results on Monday, May 11, 2020
May 04, 2020 09:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...